INMDInMode Ltd.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−3% a year). Little growth is priced in even as revenue fell 7% a year over three years, potential value, or a value trap.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What INMD's price assumes
InMode Ltd. trades at 9.84× earnings against 25.8× for the median Medical Devices name, cheaper than its own group.
Trailing P/E · Medical Devices median 25.8 · cheaper than the typical name in its group
- Free cash flow yield
- 9.8%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- −3.4%
Growth the price implies · The price pays for −3.4% free cash flow growth a year for a decade; the business has delivered −22% a year over the last three.
Details›
- Healthcare median P/E509 names
- 26.0
- Medical Devices median P/E64 names
- 25.8
- Free cash flow, trailing twelve months
- $84M
- Market capitalisation
- $856M
- 3-year revenue growth
- −6.6%
- 3-year free cash flow growth
- −22%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #2 of 51 by RyuScore